Huntington Study Group Announces 2024 Annual Meeting

Huntington Study Group Announces 2024 Annual Meeting

Rochester, NY, January 23, 2024 — The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), is pleased to announce that its annual meeting for 2024 is slated to take place from November 6-9 at the Hyatt Regency in Cincinnati, OH.

HSG has strong connections to Ohio with longtime credentialed investigators and coordinators at five HSG credentialed sites across the state, including University of Cincinnati and The Ohio State University, where HSG Executive Membership Committee Co-Chair, Dr. Sandra Kostyk, serves as Clinical Professor of Neurology. The meeting is being planned collaboratively with the local teams to ensure a synergistic approach toward developing cutting edge symposia, inspiring thought-provoking discourse, and engaging the HD community while meeting the diverse needs of seasoned HD professionals, community members, and people who are newer to the disease.

Dr. Andrew Duker, Professor of Clinical Neurology at University of Cincinnati, said, “We are incredibly honored to host the Huntington Study Group’s 2024 meeting here in Cincinnati. Ohio has always played a pivotal role in the history of HD, as nearby Middleport, Ohio was the site of George Huntington’s presentation of his paper ‘On Chorea’ in 1872 that first described the disease we now know as HD. From our history to our future, the power of collaboration and the advancement of research in HD, driven by organizations like the HSG, has allowed the development of new therapies and hopefully soon new cures for this devastating disease.”

HSG has hosted an annual meeting since 1993 to bring together, grow, and strengthen their global network of Huntington’s disease experts. The multi-day scientific conference and Family Day symposium are an opportunity for clinical trialists, researchers, clinicians, healthcare professionals, community members, and industry to learn about the latest HD research advancements, best practices that are shaping the future of HD, and most importantly, to make meaningful connections that drive collaboration, innovation, and excellence.

“HSG’s annual meeting is a dynamic convergence of minds dedicated to advancing our collective mission of accelerating treatments that make a difference for HD. Our gathering serves as a platform for Huntington’s disease experts, thought leaders, and visionaries to forge new pathways toward transformative solutions and to work together to improve the lives of people impacted by HD,” said Shari Kinel, HSG CEO.

You May Also Like

More From Author

+ There are no comments

Add yours